Contact

 

 

 

Steen Uldall HansenSteeen Uldall Hansen

Chief Scientific Officer

Doctor of Philosophy (PhD), Bioorganic chemistry.

Chief Scientific Officer and cofounder of Hepoligo Solutions Aps.

Phone: +45 60559901

Email: steen@hepoligo.com

 

 

  


  

Tom Koch SvennesenTom Koch Svennesen

Chief Executive Officer

Master Degree in chemistry.

Chief Executive Officer and cofounder of Hepoligo Solutions Aps.

Email: tom@hepoligo.com

 

 

 


  

 

 

Kirsten Winther

 

 Kirsten Winther is investment manager at Syddansk Innovation (SDI). SDI is a micro venture fund investing in high tech start-ups in the pre-seed face. Kirsten is responsible for SDI´s investment in a portfolio of start-ups covering the field of biotech, medtech, IoT and robotics. Prior to joining SDI, Kirsten has gained experience in the fields of business development, M&A, sales management and investment in energy projects, both in large corporations and as commercial director and co-investor in a start-up within greentech. Kirsten holds a MSc(econ).

 

 

 

 

 

 

 

 


 

 

Allan RosetzskyAllan Rosetzsky

 

Allan Rosetzsky is MD from Copenhagen University and consultant in general medicine and surgery. After 8 years in the clinic he joined Rhône-Poulenc (now Sanofi-Aventis) for 14 years first as Nordic Medical Director later as World Wide Medical Director based in the head quarters in Paris for 5 years responsible for clinical operations in development and medical affairs for all products including medical evaluation in connection with license opportunities. 

He founded the Contract Research Organization KLIFO in 1994 which became operational in eight countries. KLIFO was sold to a Danish investor group in 2007. He then joined the start up protein expression company Expres2ion Biotechnologies as Business Angel in 2010 and was fulltime operational in the company during the set-up period. The company had its Initial Public Offering at NASDAQ First North in Stockholm in July 2016 and the stock has gone through a very positive development since.

Allan Rosetzsky is conversant with the pharmaceutical industry top management and speaks their language (English, French, German and Scandinavian)